Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion Wipeout

5. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q4 2024: 98

Johnson & Johnson (NYSE:JNJ) is one of the largest pharmaceutical companies in the world. It spent 2024 battling several headwinds, including a massive cancer lawsuit and regulations that targeted its products for Medicare benefits. In 2025, Johnson & Johnson (NYSE:JNJ)’s shares have gained 15% as the firm has benefited from market volatility. Investors prefer stocks like JNJ when they are uncertain about the future, as a stable and sizable business offers relief. Cramer’s comments about Johnson & Johnson (NYSE:JNJ) surrounded this theme:

“David Faber often asks me, what’s the key to this market? I’m gonna have to give three keys, I’m sorry, lot of doers. SJ Smucker, SJM, Colgate, and JNJ. . . .JNJ has moved up mightily and it’s right at the level where it can either break out or be repelled. Not sure about this. And, what I’m saying is this these three have been bid up unnaturally by this program, which is out of the really good stocks of companies that are doing really well. And then to the companies, and I don’t mean to slight JNJ, but it’s been suboptimal. Well anyway, this is the breakout level for JNJ. If this market is going to bottom, JNJ has to be thrown back to the 160 level. . .Where they began these ascents. These companies are not doing well enough to be able to support the rallies that they’ve had. It’s entirely done by traders who don’t seem to know how to trade by putting things on immediately. I wish I had worked these orders, you wouldn’t see this action.”

“And I have to tell you the one that has to, remember you need to see JNJ down, you need to see Smucker down, because that’s where all the money went to. And that was ridiculous. That’s just a program done, again, by incredibly sloppy traders who don’t know how to trade.”